Trandolapril reduced total mortality in patients with stable coronary disease and reduced renal function (adjusted HR 0.73; 95% CI 0.54-1.00), but not in those with preserved renal function.
RCT (n=8,290)
Randomly assigned
Hazard Ratio: 0.73 (95% CI 0.54–1)
p-value: p=0.02
BACKGROUND: Patients with reduced renal function are at increased risk for adverse cardiovascular outcomes. In the post-myocardial infarction setting, angiotensin-converting enzyme (ACE) inhibitors have been shown to be as effective in patients with impaired renal function as in those with preserved renal function. METHODS AND RESULTS: We assessed the relation between renal function and outcomes, the influence of ACE inhibition on this relation, and whether renal function modifies the effectiveness of ACE inhibition in patients with stable coronary artery disease and preserved systolic function enrolled in the Prevention of Events with ACE inhibition trial (PEACE). Patients (n=8290) were randomly assigned to receive trandolapril (target, 4 mg/d) or placebo. Clinical creatinine measures were available for 8280 patients before randomization. The estimated glomerular filtration rate (eGFR) was calculated with the 4-point Modification of Diet in Renal Disease equation. Renal function was related to outcomes, and the influence of ACE-inhibitor therapy was assessed with formal interaction modeling. The mean eGFR in PEACE was 77.6+/-19.4, and 1355 (16.3%) patients had reduced renal function (eGFR <60 mg.mL(-1).1.73 m(-2)). We observed a significant interaction between eGFR and treatment group with respect to cardiovascular and all-cause mortality (P=0.02). Trandolapril was associated with a reduction in total mortality in patients with reduced renal function (adjusted HR, 0.73; 95% CI, 0.54 to 1.00) but not in patients with preserved renal function (adjusted HR, 0.94; 95% CI, 0.78 to 1.13). CONCLUSIONS: Although trandolapril did not improve survival in the overall PEACE cohort, in which mean eGFR was relatively high, trandolapril reduced mortality in patients with reduced eGFR. These data suggest that reduced renal function may define a subset of patients most likely to benefit from ACE-inhibitor therapy for cardiovascular protection.
Solomon et al. (Tue,) conducted a rct in Stable coronary artery disease and preserved systolic function (n=8,290). Trandolapril vs. Placebo was evaluated on Total mortality in patients with reduced renal function (adjusted HR 0.73, 95% CI 0.54 to 1.00, p=0.02). Trandolapril reduced total mortality in patients with stable coronary disease and reduced renal function (adjusted HR 0.73; 95% CI 0.54-1.00), but not in those with preserved renal function.